Ash Stevens, Inc.(ASI), a provider of contract pharmaceutical chemical development and active pharmaceutical ingredient (API) manufacturing services, reports that the US Food and Drug Administration (FDA) has approved ASI’s facility in Riverview, Michigan for the manufacture of the API, ixazomib, an oral proteasome inhibitor indicated in combination with leanlidomide and dexamethasone for the treatment of patients multiple myeloma who have received at least one prior therapy.

Source: Ash Stevens